Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

UnknownOBSERVATIONAL
Enrollment

103

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2022

Conditions
Chronic Hepatitis C
Interventions
DRUG

Daclatasvir and Asunaprevir

Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.

Trial Locations (10)

14584

Soon Chun Hyang University Bucheon Hospital, Bucheon-si

15355

Korea University Ansan Hospital, Ansan

21565

Gachon University Gil Medical Center, Incheon

22332

Inha University Hospital, Jung-gu

26426

Wonju severance christian hospital, Wŏnju

31151

Soonchunhyang University Cheonan Hospital, Cheonan

03722

Severance hospital, Seoul

04401

Soonchunhyang University Hospital, Seoul

04763

Hanyang university hospital, Seoul

07985

Ewha Womans University Mokdong Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seoul National University Boramae Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Inha University Hospital

OTHER

collaborator

Korea University

OTHER

collaborator

Gachon University Gil Medical Center

OTHER

collaborator

Hanyang University Seoul Hospital

OTHER

collaborator

Ewha Womans University Mokdong Hospital

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sang Gyune Kim

OTHER